CGP7930:: A positive allosteric modulator of the GABAB receptor

被引:33
作者
Adams, C. L.
Lawrence, A. J. [1 ]
机构
[1] Howard Florey Inst, Parkville, Vic 3010, Australia
[2] Monash Univ, Victorian Coll Pharm, Dept Pharmaceut Biol, Clayton, Vic 3168, Australia
[3] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia
来源
CNS DRUG REVIEWS | 2007年 / 13卷 / 03期
关键词
alcohol; drug-seeking; CGP7930; GABA(B) receptors;
D O I
10.1111/j.1527-3458.2007.00021.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
CGP7930 (3-(3',5'-Di-tert-butyl-4'-hydroxy)phenyl-2,2-dimethylpropanol) is a positive allosteric modulator of the metabotropic GABA(B) receptor. CGP7930 has been found to modulate the GABA(B) receptor in the open, or high affinity, state increasing agonist affinity for the receptor and signal transduction efficacy following agonist stimulation. The GABA(B) heteromeric subunit B2, involved in signal transduction but not ligand binding, seems to be the site of action of CGP7930 and similar allosteric modulators. When administered alone in naive animals, CGP7930 acts as an anxiolytic in rodents without other overt behavioral effects and has also been demonstrated to reduce self-administration of nicotine, cocaine, or alcohol in rodents, suggesting that "fine tuning" of the GABA(B) receptor by positive allosteric modulators may be able to regulate abuse of these drugs. Baclofen, the GABA(B) agonist, is currently finding use in treating addiction and various other disorders, but this can result in off-target effects and tolerance. CGP7930 when co-administered with baclofen enhances its potency, which could in theory minimize deleterious effects. Further study of CGP7930 is required, but this compound, and others like it, holds potential in a clinical setting.
引用
收藏
页码:308 / 316
页数:9
相关论文
共 37 条
[1]   Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam [J].
Addolorato, G ;
Leggio, L ;
Abenavoli, L ;
Agabio, R ;
Caputo, F ;
Capristo, E ;
Colombo, G ;
Gessa, GL ;
Gasbarrini, G .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (03) :276.e13-276.e18
[2]   Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study [J].
Addolorato, G ;
Caputo, F ;
Capristo, E ;
Domenicali, M ;
Bernardi, M ;
Janiri, L ;
Agabio, R ;
Colombo, G ;
Gessa, GL ;
Gasbarrini, G .
ALCOHOL AND ALCOHOLISM, 2002, 37 (05) :504-508
[3]   Characterization of the binding of[3H]CGP54626 to GABAB receptors in the male bullfrog (Rana catesbeiana) [J].
Asay, Matthew J. ;
Boyd, Sunny K. .
BRAIN RESEARCH, 2006, 1094 :76-85
[4]   Molecular diversity, trafficking and subcellular localization of GABAB receptors [J].
Bettler, Bernhard ;
Tiao, Jim Yu-Hsiang .
PHARMACOLOGY & THERAPEUTICS, 2006, 110 (03) :533-543
[5]   Molecular mechanisms of GABAB receptor activation:: new insights from the mechanism of action of CGP7930, a positive allosteric modulator [J].
Binet, V ;
Goudet, C ;
Brajon, C ;
Le Corre, L ;
Acher, F ;
Pin, JP ;
Prézeau, L .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :871-872
[6]   The heptahelical domain of GABAB2 is activated directly by CGP7930, a positive allosteric modulator of the GABAB receptor [J].
Binet, V ;
Brajon, C ;
Le Corre, L ;
Acher, F ;
Pin, JP ;
Prézeau, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (28) :29085-29091
[7]   GABAB RECEPTORS AND THEIR SIGNIFICANCE IN MAMMALIAN PHARMACOLOGY [J].
BOWERY, N .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (10) :401-407
[8]   Case report - Suppression of symptoms of alcohol dependence and craving using high-dose baclofen [J].
Bucknam, William .
ALCOHOL AND ALCOHOLISM, 2007, 42 (02) :158-160
[9]   In vivo effectiveness of CGP7930, a positive allosteric modulator of the GABAB receptor [J].
Carai, MAM ;
Colombo, G ;
Froestl, W ;
Gessa, GL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 504 (03) :213-216
[10]   Differential modulation by the GABAB receptor allosteric potentiator 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol(CGP7930) of synaptic transmission in the rat hippocampal CA1 area [J].
Chen, Y ;
Menendez-Roche, N ;
Sher, E .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (03) :1170-1177